Generalized anxiety disorder (GAD) is a common, chronic, and frequently disabling condition defined by excessive and difficult-to-control worry across multiple domains, accompanied by physical and cognitive symptoms of arousal. In DSM-5-TR it sits within the Anxiety Disorders chapter and requires at least six months of symptoms with associated impairment; ICD-11 retains a similar construct but loosens the duration requirement and emphasizes apprehension and tension. Lifetime prevalence approaches 5-9% in community samples, with roughly two-thirds of patients first presenting with somatic complaints rather than worry, which is why so much GAD is missed in primary care. First-line treatment combines an SSRI or SNRI with cognitive behavioral therapy, with benzodiazepines reserved for short-term, time-limited use. The bottom line: GAD is treatable, but undertreatment, benzodiazepine drift, and missed comorbidity drive most of the long-term morbidity.

GAD is among the most prevalent anxiety disorders in primary care and the second most common psychiatric diagnosis encountered in general medical settings after depression. Onset is typically gradual, and the condition runs a chronic, fluctuating course over decades.

Prevalence and demographics

• Lifetime prevalence in U.S. community samples is approximately 5-9%; 12-month prevalence is roughly 2-3%.^1-2
• Female-to-male ratio is approximately 2:1, consistent across most epidemiologic surveys.¹
• Median age of onset is approximately 30 years, later than most other anxiety disorders, with a wide distribution from adolescence through late life.¹
• Point prevalence in primary care is substantially higher than community estimates, reaching 7-8% in some samples.³

Risk factors

• Family history of anxiety or mood disorders, with heritability estimates of approximately 30%.⁴
• Female sex, adverse childhood experiences, behavioral inhibition in childhood, and neuroticism as a personality trait.
• Chronic medical illness, particularly cardiopulmonary disease, irritable bowel syndrome, and chronic pain.
• Lower socioeconomic status and recent life stressors.

Comorbidity

• Lifetime comorbidity with major depressive disorder approaches 60-70%; this is the rule rather than the exception.^1-2
• High comorbidity with other anxiety disorders (panic disorder, social anxiety disorder, specific phobia) and with alcohol and sedative use disorders.
• GAD is independently associated with increased suicidal ideation and attempts, even after controlling for depression.⁵

GAD reflects dysregulation of fear and worry circuitry, with hyperactive amygdala-driven threat detection inadequately modulated by prefrontal control regions. No single neurobiologic lesion explains the disorder; current models integrate genetic vulnerability, neurotransmitter imbalance, and learned cognitive patterns.

Neurocircuitry

• Hyperactivation of the Amygdala in response to ambiguous or negatively valenced stimuli, with reduced top-down regulation by ventromedial and dorsolateral prefrontal cortex.⁶
• Altered functional connectivity within the Default mode network and salience network has been reported, with the salience network implicated in the persistent attentional bias toward threat.⁶
• Structural imaging findings are inconsistent and not diagnostically useful.

Neurotransmitter systems

• Serotonergic and noradrenergic dysregulation underlies the efficacy of SSRIs and SNRIs.
• GABAergic hypofunction is the rationale for benzodiazepine efficacy and for the short-term role of pregabalin.
• Glutamatergic abnormalities and HPA-axis dysregulation are areas of active investigation but not yet clinically actionable.

Genetics and environment

• Twin studies estimate heritability around 30%, lower than for bipolar disorder or schizophrenia.⁴
• No replicated single-gene findings; risk is polygenic and overlaps substantially with major depressive disorder, suggesting shared internalizing-disorder vulnerability.⁴
• Childhood adversity, parental overprotection or rejection, and chronic interpersonal stress are robust environmental contributors.

Cognitive models

• Intolerance of uncertainty is a central cognitive vulnerability — patients overestimate threat and underestimate their coping resources.
• Worry is reinforced as a maladaptive cognitive avoidance strategy that suppresses somatic anxiety in the short term but maintains it long term.⁷

DSM-5-TR places GAD within the Anxiety Disorders chapter and requires excessive, difficult-to-control worry occurring more days than not for at least six months, accompanied by physical symptoms and clinically significant impairment.⁸

DSM-5-TR criteria

• Excessive anxiety and worry about a number of events or activities, occurring more days than not for at least six months.
• The worry is difficult to control.
• The anxiety and worry are associated with at least three of six physical or cognitive symptoms in adults (only one is required in children):
  • Restlessness or feeling keyed up or on edge
  • Being easily fatigued
  • Difficulty concentrating or mind going blank
  • Irritability
  • Muscle tension
  • Sleep disturbance (initial insomnia, restless sleep, or unsatisfying sleep)
• The disturbance causes clinically significant distress or functional impairment.
• The symptoms are not attributable to a substance, medication, or another medical condition, and are not better explained by another mental disorder.⁸

Specifiers and severity

• DSM-5-TR does not assign formal specifiers to GAD beyond the standard mild/moderate/severe descriptors used clinically.
• Severity is generally graded with validated scales such as the GAD-7 rather than DSM-5-TR descriptors.

The clinical hallmark is uncontrollable worry across multiple domains — health, family, finances, work, minor logistics — coupled with somatic tension that often dominates the presentation. Most patients describe the worry as lifelong or longstanding and cannot identify a discrete onset.

Cognitive features

• Worry that is generalized across domains rather than focused on a single trigger (which would suggest a specific phobia or social anxiety disorder).
• Intolerance of uncertainty — distress provoked by ambiguity rather than by identifiable threats.
• Anticipatory thinking, mental rehearsal of worst-case scenarios, and difficulty disengaging from the worry stream.
• Patients commonly describe the worry as ego-dystonic and exhausting but feel unable to stop it.

Somatic features

• Muscle tension is the most specific somatic symptom and frequently the chief complaint, often presenting as neck, shoulder, or jaw pain, or as tension headaches.
• Fatigue, restlessness, and disturbed sleep — typically initial insomnia from rumination at bedtime.
• Autonomic symptoms (palpitations, GI distress, dizziness) are common but less prominent than in panic disorder.

Course and prototypical presentation

• Onset is gradual; many patients report "always being a worrier."
• Course is chronic and fluctuating, with symptom intensity tracking life stressors.
• Spontaneous remission is uncommon; full remission rates without treatment are low and relapse is the norm.¹⁰
• The prototypical patient is a middle-aged woman presenting to primary care with fatigue, insomnia, GI complaints, or muscle tension, who on careful interview describes pervasive worry she has lived with for years.

Red flags

• New-onset anxiety after age 40 should prompt a search for medical or substance-induced causes before settling on GAD.
• Episodic, discrete surges of fear with autonomic symptoms suggest panic disorder rather than GAD.
• Worry confined to a single feared domain (contamination, social evaluation, health) suggests another anxiety or obsessive-compulsive disorder.

GAD is a diagnosis of pattern, not exclusion, but the differential is wide because anxiety symptoms are produced by many psychiatric, medical, and substance-related conditions. Sort by domain — psychiatric, medical, substance — before settling.

Psychiatric differentials

• Major depressive disorder: Worry in MDD is congruent with depressive themes (guilt, hopelessness) and accompanied by anhedonia and neurovegetative symptoms; comorbidity is common, and both diagnoses are made when criteria for each are met.
• Panic disorder: Defined by recurrent unexpected panic attacks and anticipatory worry about further attacks; GAD worry is broader and not centered on bodily sensations.
• Social anxiety disorder: Worry is confined to social or performance situations.
• Specific phobia: Anxiety is circumscribed to a specific feared object or situation.
• Obsessive-compulsive disorder: Obsessions are intrusive, ego-dystonic, and typically accompanied by compulsions; GAD worry is about real-life problems and is not paired with neutralizing rituals.
• Posttraumatic stress disorder: Anxiety follows an identifiable traumatic event and is accompanied by intrusion, avoidance, and hyperarousal symptoms tied to the trauma.
• Adjustment disorder with anxiety: Symptoms occur within three months of an identifiable stressor and resolve within six months of its termination, falling short of full GAD duration or symptom criteria.
• Illness anxiety disorder: Worry is specifically about having a serious illness.

Medical mimics

• Hyperthyroidism — order TSH in any new anxiety presentation.
• Pheochromocytoma — episodic hypertension with paroxysmal anxiety, headache, and diaphoresis (rare but classic).
• Cardiopulmonary disease — arrhythmia, mitral valve prolapse, asthma, COPD.
• Hypoglycemia, particularly in patients on insulin or sulfonylureas.
• Carcinoid syndrome (rare).
• Neurologic — temporal lobe epilepsy, vestibular disorders, multiple sclerosis.
• Vitamin B12 deficiency and other metabolic derangements in older adults.

Substance and medication causes

• Stimulants: caffeine (often overlooked), nicotine, cocaine, methamphetamine, prescription stimulants.
• Sympathomimetics: pseudoephedrine, beta-agonists (albuterol).
• Withdrawal states: alcohol, benzodiazepines, opioids, cannabis.
• Corticosteroids, levothyroxine excess, theophylline.
• SSRI activation in early treatment can mimic worsening anxiety.

A focused history, targeted physical exam, and a small panel of labs cover the great majority of GAD presentations. The goal is to confirm the worry pattern, rule out medical mimics, and screen for the comorbidities that change management.

Interview approach

• Ask about worry domains, controllability, duration, and how worry interferes with sleep, attention, and function.
• Screen for panic attacks, social fears, obsessions, trauma history, and depressive symptoms in every patient.
• Substance history including caffeine quantification, alcohol, cannabis, stimulants, and any over-the-counter sympathomimetics.
• Suicide risk assessment — anxiety disorders independently raise suicide risk.⁵

Validated rating scales

• GAD-7: 7-item self-report; score ≥10 has good sensitivity and specificity for GAD in primary care and is the standard severity measure.¹¹
• Hamilton Anxiety Rating Scale (HAM-A): clinician-administered 14-item scale used in research and trials; less practical for routine practice.
• Penn State Worry Questionnaire (PSWQ): captures the worry construct specifically and is useful when GAD-7 is borderline.
• PHQ-9 to screen for comorbid depression at every visit.

Physical exam and labs

• Vital signs, thyroid exam, cardiopulmonary exam.
• TSH in every new presentation. CBC, comprehensive metabolic panel, and B12 in older adults or atypical presentations.
• EKG if palpitations are prominent, if a stimulant or atomoxetine is being considered, or in older patients.
• Urine toxicology when substance contribution is suspected.

What NOT to order

• Routine neuroimaging is not indicated for typical GAD presentations.
• 24-hour urinary catecholamines or metanephrines should be reserved for patients with paroxysmal hypertension or other features suggesting pheochromocytoma — the pretest probability in unselected anxious patients is vanishingly low and false positives are common.
• Panels of "adrenal fatigue" or salivary cortisol testing have no evidence base and should not be ordered.

First-line treatment for GAD pairs an SSRI or SNRI with cognitive behavioral therapy; either modality alone is acceptable, and combination is reasonable for moderate-to-severe disease. Benzodiazepines are effective short-term but are not a first-line maintenance strategy. Set expectations early: response typically takes 4-6 weeks, and remission rates are modest.

Pharmacotherapy

• First-line: an SSRI or SNRI. Strong evidence supports several agents in this class with broadly comparable efficacy; choice is driven by tolerability, drug interactions, and prior response.^12-13
  • SSRIs with FDA approval for GAD: escitalopram and paroxetine. Sertraline, citalopram, and fluoxetine are also commonly used off-label with class-level evidence.¹²
  • SNRIs with FDA approval for GAD: venlafaxine extended-release and duloxetine.¹²
  • Start low and titrate slowly — anxious patients are particularly sensitive to early activation. Typical starting doses: escitalopram 5-10 mg, sertraline 25-50 mg, venlafaxine XR 37.5-75 mg, duloxetine 30 mg.
  • Allow 4-6 weeks at therapeutic dose before judging response. Continue effective treatment for at least 6-12 months after remission to reduce relapse.¹³
• Second-line and adjunctive options:
  • Buspirone — partial 5-HT1A agonist, FDA-approved for GAD. Slow onset (2-4 weeks), no dependence liability, no sedation; useful as monotherapy in mild GAD or as augmentation, but generally less effective than SSRIs.¹⁴
  • Pregabalin — alpha-2-delta calcium channel modulator with evidence in GAD; widely used in Europe (licensed in the EU) but not FDA-approved for GAD in the United States. Faster onset than SSRIs (within 1 week). Watch for misuse, especially in patients with substance use histories.¹⁵
  • Hydroxyzine — H1 antihistamine with anxiolytic effect; useful for short-term symptomatic relief without dependence risk.¹⁶
  • Benzodiazepines — effective and rapid in onset, but limited by tolerance, dependence, cognitive effects, falls in older adults, and impairment with concurrent opioids or alcohol. Reserve for short-term use during SSRI titration or for acute exacerbations, with a defined taper plan.¹⁷
  • Tricyclic antidepressants (imipramine) have evidence in GAD but are limited by anticholinergic burden and cardiac toxicity in overdose; rarely used first-line.¹²
• Treatment-resistant GAD:
  • Confirm the diagnosis, address comorbid depression, substance use, and sleep disorders, and verify adherence and adequate dose-duration trials.
  • Switch within or across class (SSRI to SNRI, or to a different SSRI).
  • Augmentation with buspirone, pregabalin, or low-dose second-generation antipsychotics (quetiapine, aripiprazole). Limited evidence suggests benefit but harms — metabolic, sedation, EPS — often outweigh modest gains, and antipsychotics should not be routinely used.¹⁸

Psychotherapy

• Cognitive behavioral therapy (CBT) is the best-evidenced psychotherapy for GAD, with effect sizes comparable to pharmacotherapy and durable benefit after treatment ends.¹⁹
  • Core components: psychoeducation, cognitive restructuring of catastrophic thinking, worry exposure, behavioral experiments, relaxation training, and problem-solving.
  • Typical course: 12-16 weekly sessions.
• Applied relaxation has evidence comparable to CBT in some trials and is a reasonable alternative when CBT is unavailable.¹⁹
• Acceptance and commitment therapy (ACT) and mindfulness-based interventions show moderate evidence and are reasonable alternatives, particularly for patients who find traditional CBT too symptom-focused.²⁰
• Internet-delivered and guided self-help CBT shows efficacy and broadens access, particularly in primary care.²¹

Neuromodulation

• ECT, TMS, and other neuromodulation modalities are not standard treatments for GAD and have very limited evidence; they should not be offered for primary GAD outside specialized research settings.

Adjunctive

• Sleep hygiene and treatment of comorbid insomnia.
• Reduction or elimination of caffeine, nicotine, and alcohol.
• Aerobic exercise — moderate evidence suggests modest anxiolytic benefit, with effect sizes smaller than first-line treatments but a favorable harm profile.²²
• Treatment of comorbid medical conditions (thyroid, cardiopulmonary, pain) often reduces anxiety symptom burden.

Most first-line GAD pharmacotherapies are well-tolerated but carry meaningful adverse effects, and the evidence base over-represents short-term efficacy in selected trial populations. Long-term tolerability and real-world effectiveness data are thinner than the response-rate figures suggest.

Common adverse effects

• SSRIs and SNRIs: nausea, headache, insomnia or somnolence, sexual dysfunction (often persistent), and early activation that can transiently worsen anxiety.¹²
• Benzodiazepines: sedation, psychomotor slowing, anterograde amnesia, falls in older adults, and rebound anxiety with discontinuation.¹⁷
• Pregabalin: sedation, dizziness, weight gain, peripheral edema, and emerging recognition of misuse potential.¹⁵
• Buspirone: dizziness, headache, nausea; generally well-tolerated.

Serious or rare adverse effects

• SSRIs/SNRIs: hyponatremia (especially in older adults), bleeding risk (particularly with NSAIDs or anticoagulants), QT prolongation (citalopram dose-dependent), serotonin syndrome with serotonergic combinations, and an FDA boxed warning for suicidality in patients under 25.
• Venlafaxine: dose-dependent hypertension at doses above 225 mg/day.
• Benzodiazepines: respiratory depression and overdose mortality, particularly with concurrent opioids or alcohol; FDA boxed warning for opioid co-prescription.¹⁷
• Tricyclics: cardiac conduction abnormalities and lethality in overdose.

Discontinuation and monitoring

• SSRI/SNRI discontinuation syndrome — flu-like symptoms, dizziness, paresthesias ("brain zaps"), insomnia. More pronounced with paroxetine and venlafaxine; mitigated by gradual taper.
• Benzodiazepine discontinuation — withdrawal anxiety, insomnia, tremor, and at high doses or after prolonged use, seizures and delirium. Always taper.
• Routine monitoring includes symptom rating (GAD-7), suicidality, side effects, and adherence at each visit during titration.

Limitations of the evidence

• Industry-sponsored trials dominate the GAD pharmacotherapy literature, with relatively short follow-up (typically 8-12 weeks) and selected populations excluding common comorbidities.
• Head-to-head comparisons among SSRIs, SNRIs, and pregabalin are limited; most claims about comparative efficacy rest on indirect comparisons.
• Long-term efficacy and harm data beyond one year are sparse for nearly all agents.
• Psychotherapy trials face blinding limitations and therapist-allegiance effects.

GAD presents and is managed differently across the lifespan and in the presence of comorbid medical conditions. The general principle is the same — SSRI/SNRI plus CBT — but dosing, drug selection, and monitoring shift.

Pediatric

• GAD is the most common anxiety disorder in adolescence; symptoms often manifest as perfectionism, somatic complaints, and reassurance-seeking.
• CBT is first-line. SSRIs (sertraline, fluoxetine, escitalopram) are added for moderate-to-severe disease; the CAMS trial demonstrated superiority of combined CBT plus sertraline over either monotherapy in pediatric anxiety disorders, including GAD.²³
• Monitor for activation and suicidality per the FDA boxed warning in patients under 25.

Geriatric

• GAD is common in older adults but underdiagnosed; presentation is dominated by somatic and sleep complaints.
• Avoid benzodiazepines where possible — falls, fractures, delirium, and cognitive impairment risks are substantial; included on the AGS Beers Criteria as potentially inappropriate.²⁴
• SSRIs and SNRIs are first-line; start low and go slow. Watch for hyponatremia and bleeding risk.
• CBT is effective in older adults and should be offered.

Perinatal

• Untreated antenatal anxiety is associated with adverse obstetric and neonatal outcomes; treatment decisions weigh medication exposure against the harms of untreated illness.
• Sertraline is generally preferred among SSRIs in pregnancy and lactation given a relatively favorable safety profile.²⁵
• Avoid paroxetine in the first trimester because of associations with cardiac malformations.²⁵
• Benzodiazepines in late pregnancy are associated with neonatal sedation and withdrawal; use only when essential.
• CBT is first-line when severity allows.

Comorbid medical illness

• Cardiac disease — SSRIs are generally preferred over TCAs and venlafaxine; monitor citalopram dose for QT prolongation.
• Hepatic impairment — duloxetine is contraindicated.
• Chronic pain — duloxetine and pregabalin offer dual benefit.
• Migraine — venlafaxine has prophylactic evidence and may serve a dual role.

Comorbid substance use

• Treat the substance use disorder concurrently; benzodiazepines should generally be avoided given high abuse liability.
• Pregabalin should be used cautiously in patients with substance use histories given emerging misuse data.¹⁵
• Buspirone, hydroxyzine, SSRIs, and SNRIs are preferred.

Cultural considerations

• Somatic presentations of anxiety predominate in many non-Western cultures; culturally sensitive interviewing improves detection.
• Cultural idioms of distress (e.g., "nervios," "thinking too much") may map onto GAD but require careful contextual interpretation.

GAD is chronic and recurrent for most patients, but treatment meaningfully improves trajectory. Long-term naturalistic studies show that fewer than 40% of patients achieve sustained remission within five years without treatment.¹⁰

Course

• Chronic and fluctuating, with symptom waxing and waning around life stressors.
• Comorbidity with depression worsens prognosis and complicates pharmacotherapy choices.
• Spontaneous remission is uncommon; most untreated patients remain symptomatic for years.¹⁰

Treatment outcomes

• Response (≥50% symptom reduction) occurs in approximately 50-65% of patients on first-line pharmacotherapy.¹²
• Full remission rates are lower, in the 30-40% range at 12 weeks.¹²
• Maintenance treatment for at least 6-12 months after remission reduces relapse; many patients benefit from longer treatment.¹³
• CBT effects are typically durable, with continued benefit at 6-12 month follow-up.¹⁹

Suicide and mortality

• GAD is independently associated with increased suicidal ideation and attempts; risk rises substantially with comorbid depression or alcohol use.⁵
• All-cause mortality is modestly elevated, mediated largely by cardiovascular disease and comorbid substance use.

Functional outcome

• Even partial response improves function; work productivity, sleep, and quality of life are sensitive markers.
• Untreated GAD is associated with substantial occupational and interpersonal impairment, comparable in some studies to major depression.

GAD itself rarely produces psychiatric emergencies, but the comorbidities and the consequences of mismanagement frequently do. Emergency presentations are usually about something else happening on top of GAD.

Hospitalization criteria

• Active suicidal ideation with plan or intent, particularly with comorbid depression or substance use.
• Severe functional decompensation that cannot be managed in outpatient or partial hospital settings.
• Severe benzodiazepine or sedative withdrawal — a medical emergency that may require inpatient detoxification.

Suicide risk markers

• Comorbid major depressive disorder, alcohol use disorder, and prior suicide attempts are the strongest predictors.⁵
• Acute insomnia, hopelessness, and recent psychosocial losses raise short-term risk.

Acute agitation

• Verbal de-escalation and a low-stimulation environment first.
• For severe agitation, oral lorazepam or short-acting benzodiazepine is reasonable; reserve antipsychotics for agitation in the context of psychosis or delirium.

Several persistent debates shape contemporary GAD management. None has a settled answer, and clinicians should know where guidelines diverge.

Regulatory and prescribing differences

• Pregabalin is licensed for GAD in the European Union but not in the United States; U.S. clinicians use it off-label, which complicates coverage and prescribing norms.¹⁵
• Quetiapine extended-release has RCT evidence in GAD and is licensed in some jurisdictions but not the United States; benefits are offset by metabolic and sedation harms.¹⁸

Boundaries with depression

• The high comorbidity and shared genetic vulnerability between GAD and MDD have driven debate about whether GAD is best conceptualized as a distinct disorder or as part of a broader "distress" spectrum within the internalizing disorders.⁴
• ICD-11 and DSM-5-TR retain GAD as a discrete category, but research diagnostic frameworks (HiTOP, RDoC) place it dimensionally.

Benzodiazepine controversy

• Practice patterns diverge sharply by country and specialty; some clinicians argue that long-term, low-dose benzodiazepines are appropriate for selected patients who have failed other treatments, while most guidelines counsel against this. Evidence on long-term harms continues to accumulate.¹⁷

Cannabis and CBD

• Patients increasingly self-medicate with cannabis or cannabidiol products. Evidence for efficacy in GAD is limited and inconsistent; cannabis use is associated with worsening anxiety in some patients and with substance use disorder risk.²⁶

Digital and brief interventions

• Internet-delivered CBT and brief primary-care interventions show efficacy and may close access gaps, but quality control across platforms is uneven and integration with usual care is inconsistent.²¹

• DSM-5-TR GAD requires excessive worry on more days than not for at least six months, plus three of six physical/cognitive symptoms in adults (only one in children).⁸
• The six somatic/cognitive symptoms are restlessness, fatigue, concentration difficulty, irritability, muscle tension, and sleep disturbance.⁸
• Median age of onset is approximately 30 years — later than most other anxiety disorders.¹
• Female-to-male ratio is approximately 2:1.¹
• Lifetime comorbidity with major depressive disorder is approximately 60-70%.^1-2
• First-line pharmacotherapy is an SSRI or SNRI; FDA-approved agents for GAD include escitalopram, paroxetine, venlafaxine XR, and duloxetine.¹²
• Buspirone is a 5-HT1A partial agonist FDA-approved for GAD with no dependence liability and slow onset.¹⁴
• Pregabalin is licensed for GAD in the European Union but not in the United States.¹⁵
• Benzodiazepines should be limited to short-term use; co-prescription with opioids carries an FDA boxed warning for overdose.¹⁷
• The GAD-7 is the standard severity measure in primary care; a score ≥10 has good sensitivity and specificity for GAD.¹¹
• TSH should be checked in any new anxiety presentation; hyperthyroidism is the most common medical mimic.
• Citalopram has a dose-dependent QT prolongation warning, with a maximum recommended dose of 40 mg/day (20 mg/day in patients over 60 or with hepatic impairment).
• CBT effect sizes for GAD are comparable to first-line pharmacotherapy and benefits are durable after treatment ends.¹⁹
• Sertraline is generally preferred among SSRIs in pregnancy; paroxetine is avoided in the first trimester.²⁵
• New-onset anxiety after age 40 should prompt a search for medical or substance-induced causes before settling on a primary GAD diagnosis.

No external funding. No conflicts of interest declared. Peer-review status: pending.